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INTRODUCTION:  Cerebral  arteriovenous  malformations  (AVM)  usually  present  with headache,  hemor-
rhage,  or  seizure.  Erythropoietin  (EPO)  has demonstrated  protective  effects  against  ischemia  within  the
CNS.
PRESENTATION  OF  CASE:  The  authors  report  a  patient  with  a cerebral  AVM  and  concurrent  polycythemiaeywords:
rteriovenous malformation
olycythemia
rythropoietin
icrosurgical  resection
eurosurgical procedures
associated  with  elevated  serum  EPO.  Systemic  EPO  levels  declined  acutely  after  resection  of  the  patient’s
AVM,  and  the polycythemia  resolved  in  the  following  months.
DISCUSSION: Polycythemia  secondary  to  a  cerebral  AVM,  in the  absence  of  extra-cerebral  vascular  lesions,
has  not  been  described  in the literature.
CONCLUSION: The  authors  explore  the  mechanisms  by  which  this  patient’s  cerebral  AVM  could  have
induced  EPO  production  within  the  brain,  manifesting  as  polycythemia.
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. Introduction
Cerebral arteriovenous malformations (AVM) occur in 1.3 per
00,000 adults per year.1 Although AVMs are relatively infrequent,
hey are an important cause of neurological morbidity. They usually
resent with generalized or focal seizures, persistent or progressive
eurological deﬁcit, and headache.2 Most importantly, AVMs cause
ew or recurrent intracranial hemorrhage (4–6% per year).2
Polycythemia has been described as a rare occurrence among
atients harboring pulmonary AVMs.3–5 The etiology of poly-
ythemia is believed to be due to decreased oxygen saturation
econdary to arteriovenous shunting.3–5 To the best of our
nowledge, polycythemia secondary to a cerebral AVM, without
ssociated pulmonary vascular lesions, has not been previously
Abbreviations: AVM, arteriovenous malformations; BBB, blood–brain barrier;
PO, erythropoietin; VEGF, vascular endothelial growth factor; TNF, tumor necrosis
actor-alpha; MRI, magnetic resonance imaging.
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described. Herein, we  present a patient with a cerebral AVM
and concurrent polycythemia whose elevated erythropoietin (EPO)
levels and polycythemia normalized acutely after microsurgical
resection of his AVM.
2.  Presentation of case
A  37-year-old man  presented with a 3-month history of
increased fatigue and worsening headaches. Past medical history
was signiﬁcant for left eye blindness, a 20 pack-year smoking his-
tory, and alcohol abuse. Laboratory tests revealed polycythemia
(hemoglobin 20.5 g/dL and hematocrit 58%). One year before pre-
sentation, his hemoglobin level was  slightly above normal limits
(18.6 g/dL).
Genetic analysis was  negative for a JAK-2 mutation and serum
erythropoietin level was  elevated on 2 occasions at 63 and 75
(normal 2.6–18.5 mU/mL). Imaging and systemic workup was oth-
erwise negative for any ectopic EPO-producing tumor, especially in
the kidneys or adrenals. An evaluation of his headaches included
an MRI  of the brain which demonstrated a left medial frontal
3.2 cm × 1.5 cm × 1.3 cm AVM (Fig. 1).
The patient underwent 500-mL phlebotomies on 5 separate
occasions which improved his headaches for 1–2 days. A cerebral
angiogram demonstrated an AVM fed mainly by the left pericallosal
Open access under CC BY-NC-ND license.artery (Fig. 2). He subsequently underwent microsurgical resection
of his AVM through a right interhemispheric transﬂacine approach
without any complication. Intraoperative observations were con-
sistent with an AVM (Fig. 3). Multiple phlebotomy sessions were
s Ltd. Open access under CC BY-NC-ND license.
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Fig. 1. Axial (A), sagittal T2 (B), and sagittal T1 (C) with contrast MRI  images demonstrate a left medial frontal 3.2 cm × 1.5 cm × 1.3 cm AVM.
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ﬂig. 2. Cerebral angiogram images: AP-early arterial phase (A), AP-early venous p
ericallosal artery.
ble to accomplish a pre-operative hemoglobin of 15.8 (g/dL) and
ematocrit of 46.7%. Pre-operative oxygen saturation was  100% and
he patient showed no signs of hypoxia. Intra- and postoperative
maging conﬁrmed adequate resection of the AVM (Fig. 4).Histological examination conﬁrmed the presence of an AVM
ithout any evidence of neoplasia (Fig. 5). In the ﬁrst few postop-
rative hours, his erythropoietin levels declined to 13.8 (mU/mL),
nd then to 7.8 (mU/mL) by 24 h.
ig. 3. This AVM was exposed and resected through a right interhemispheric trans-
acine approach. Intraoperative observations were consistent with an AVM.B), and lateral-late arterial phase (C) demonstrate an AVM fed mainly by the left
Six months postoperatively, the patient’s polycythemia resolved
with erythropoietin of 9.2 (mU/mL), a normal hemoglobin of 14.6
(g/dL), and a hematocrit of 46.2%. The patient did not receive
any additional phlebotomies postoperatively. One year after cran-
iotomy, his hemoglobin was 16.2 (g/dL) and hematocrit was  48.3%.
The patient’s headaches resolved postoperatively.
3. Discussion
We  describe a patient whose polycythemia resolved shortly
after surgical resection of his cerebral AVM. Given the abrupt
decline of erythropoietin (EPO) levels postoperatively, we  believe
that the patient’s polycythemia was due to erythropoietin produc-
tion associated with his AVM. To our knowledge, an association
between isolated cerebral AVMs and secondary polycythemia has
not been described previously in the literature. There are reports
of excessive EPO production associated with pulmonary AVMs.4
Although the exact mechanism of erythropoietin production by
AVMs is not known at this time, one proposed mechanism is
decreased blood oxygenation due to pulmonary shunting.3,5 This
does not appear to be the case with cerebral AVMs as the blood
in the cerebral circulation has already been oxygenated; however,
local vascular steal due to shunting within the brain could con-
tribute to EPO production.
The central nervous system has recently been implicated in
EPO production.6 Cerebral EPO production functions primarily in
a paracrine and autocrine manner as opposed to the endocrine
manner in renal EPO. Astrocytes are the primary cerebral pro-
ducer of EPO. Although neurons produce some EPO, they are the
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pig. 4. Intraoperative post-resection late arterial angiogram images—lateral (A), AP
VM.  Postoperative axial T2 MRI  images (D, E) at 3-month follow-up conﬁrm such 
rimary recipient of this hormone’s effect.6 EPO affects neural and
rythroid progenitor cells by binding to EPO-R, causing activation
f JAK2 and triggering subsequent signal transduction pathways.7
 mutation of the JAK2 gene results in autologous erythropoiesis,
ound in up to 90% of patients with polycythemia vera.8,9 Under
ypoxic conditions, astrocytes are able to signiﬁcantly increase
heir EPO production, by as much as 100 times greater than
aseline.10 Hypoxia and brain ischemia caused by cerebral AVMs
ypically occurs through vascular steal phenomenon, stimulating
strocytes and neurons located within the AVM territory to drasti-
ally increase EPO production.
EPO harbors neuroprotective beneﬁts against cerebral ischemia.
n vivo studies in mice have demonstrated that EPO leads to smaller
ortical infarct size and decreased neurological dysfunction.11,12
PO has also been identiﬁed as a key mediator in a protec-
ive process called preconditioning. Preconditioning occurs when
 brief, sublethal episode of ischemia activates cellular signals and
athways that make neurons resistant to future severe ischemic
nsults.13 EPO may  provide neuroprotection through several mech-
nisms including anti-apoptotic, anti-inﬂammatory, neurogenic,
nd angiogenic effects.14
Another possibility is that excessive EPO production can lead to
VM pathogenesis. Kim et al., 15 proposed a “response-to-injury
aradigm,” wherein an inciting event (infection, inﬂammation,arotid injection (B) and AP-right carotid injection (C) reveal complete resection of
g.
trauma, etc.), superimposed on a structural defect or suscepti-
ble underlying genetic background, can transform the normal
response to injury into a dysplastic response. An injury to the brain
evokes a misguided response which serves to perpetuate further
insults. The associated endothelial stress due to high ﬂow rates in
AVMs are thought to lead to increased expression of angiogenic
factors and consequent lesion propagation.16,17 In fact, the over-
expression of vascular endothelial growth factor (VEGF) has been
recognized as a prevalent feature of AVMs.15,18 EPO, through its
function of inducing angiogenesis and upregulating expression of
VEGF,19 may  have contributed to the pathogenesis of our patient’s
AVM.
How can increased EPO production from a central nervous sys-
tem source manifest as a systemic disease such as polycythemia?
EPO produced by our patient’s AVM would need to cross the
blood–brain barrier (BBB) in order to result in secondary poly-
cythemia. The large size of EPO would prevent its transfer across the
intact BBB.6,7 However, AVM lesions are associated with increased
angiogenic factors, such as VEGF, and inﬂammatory cytokines,
including tumor necrosis factor-alpha (TNF) and interleukins.
These factors can result in BBB breakdown, allowing for EPO to cross
the BBB.16
This case report raises questions regarding the involvement of
EPO in the pathogenesis of AVMs. Evaluation of EPO levels among a
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Fig. 5. Arteriovenous malformation: (A) Low-power image shows a highly vascular, hemorrhagic lesion consisting of back-to-back blood vessels (H&E, 50×). The vessels
are  viable in size and thickness. (B) Note the gliotic intervening brain parenchyma, including Rosenthal ﬁbers (RF) (H&E, 250×). (C) Trichrome (50×) preparation outlines
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rhe  variably sized blood vessel walls. (D) An elastic van Gieson (50×) stain highlig
f  arterial component. (E and F) Erythropoietin immunostain (EPO H-162, rabbit po
strocytes (arrows) of the brain parenchyma immediately surrounding the arteriov
arge group of patients harboring AVMs may  further elucidate the
mportance of EPO in this patient population.
. ConclusionThis case report describes the rare occurrence of a patient with
olycythemia secondary to a cerebral AVM. Our patient’s EPO levels
eclined within hours of surgical resection and his polycythemia
esolved shortly thereafter. Although the mechanism of EPO internal elastic layer (black) in some of the blood vessels, signifying the presence
nal, Santa Cruz Biotechnology Inc., Dallas, Texas) shows overexpression in reactive
 malformation (EPO, 25×).
production by cerebral AVMs is unknown and can only be specula-
tive at this time, AVM pathogenesis and pleiotropic actions of EPO
are the subjects of signiﬁcant ongoing research. Our patient’s ele-
vated level of systemic EPO could have been secondary to a vascular
steal phenomenon. Although patients with AVMs do not com-
monly develop clinical polycythemia, AVMs possess angiogenic and
inﬂammatory traits that permit deterioration of the blood–brain
barrier (BBB), making systemic dissemination of EPO manufactured
in the central nervous system possible. Further large patient cohort
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tudies are warranted to examine the relationship between brain
VMs and EPO secretion.
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